Skip to main content
Quest Diagnostics

Fasting Intact Insulin by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) as a Predictor of Nonalcoholic Fatty Liver Disease in Pediatric Patients

American Diabetes Association 83rd Scientific Sessions

ADA 2023

San Diego, CA, June 23-26, 2023

Poster presentation: Fasting Intact Insulin by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) as a Predictor of Nonalcoholic Fatty Liver Disease in Pediatric Patients

Authors: Huneault HE, Ayinde D, He Z, Cohen CC, Ramirez A, Larsen JA, McPhaul MJ, Vos MB

Specialty: Endocrinology, Cardiology, Cardiovascular disease, Pediatrics

Related content

Conference Presentation
Differences in HDL Particle Composition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Liver Fibrosis May Explain Higher Cardiovascular Risk
Test FAQ
Insulin Intact LC MS MS
Conference Presentation
Assessment of NAFLD Burden in an Employee Wellness Program Among Non-obese Patients Without Evident Metabolic Abnormalities

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.